JP2022520061A5 - - Google Patents
Info
- Publication number
- JP2022520061A5 JP2022520061A5 JP2021546264A JP2021546264A JP2022520061A5 JP 2022520061 A5 JP2022520061 A5 JP 2022520061A5 JP 2021546264 A JP2021546264 A JP 2021546264A JP 2021546264 A JP2021546264 A JP 2021546264A JP 2022520061 A5 JP2022520061 A5 JP 2022520061A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962803299P | 2019-02-08 | 2019-02-08 | |
| US62/803,299 | 2019-02-08 | ||
| PCT/US2020/017364 WO2020163823A2 (en) | 2019-02-08 | 2020-02-07 | Therapeutic agents and methods of treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022520061A JP2022520061A (ja) | 2022-03-28 |
| JP2022520061A5 true JP2022520061A5 (https=) | 2023-05-23 |
Family
ID=71948254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021546264A Pending JP2022520061A (ja) | 2019-02-08 | 2020-02-07 | 治療薬および治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220169628A1 (https=) |
| EP (1) | EP3920923A4 (https=) |
| JP (1) | JP2022520061A (https=) |
| KR (1) | KR20210137025A (https=) |
| CN (1) | CN113660937A (https=) |
| AU (1) | AU2020218367A1 (https=) |
| CA (1) | CA3127501A1 (https=) |
| WO (1) | WO2020163823A2 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12441722B2 (en) | 2020-01-15 | 2025-10-14 | University Of Florida Research Foundation, Incorporated | Therapeutic agents and methods of treatment |
| WO2022072094A2 (en) * | 2020-08-28 | 2022-04-07 | University Of Florida Research Foundation, Incorporated | Modulators of nuclear receptor subfamily 4 group a member 1 (nr4a1) and uses thereof |
| JP2024505562A (ja) | 2021-02-02 | 2024-02-06 | レス ラボラトイレス セルビエル | 選択的ｂｃｌ－ｘｌ ｐｒｏｔａｃ化合物及び使用の方法 |
| JP2024534223A (ja) | 2021-09-01 | 2024-09-18 | シーザン ハイスーク ファーマシューティカル カンパニー リミテッド | Ｂｃｌ－２ファミリータンパク質を分解する化合物及びその医薬的な応用 |
| US20240398764A1 (en) * | 2021-10-12 | 2024-12-05 | University Of Florida Research Foundation, Incorporated | Methods of treating diseases associated with senescent cell accumulation |
| CA3241668A1 (en) | 2021-12-09 | 2023-06-15 | University Of Florida Research Foundation, Incorporated | Bcl-xl/bcl-2 dual degraders for treatment of cancers |
| KR20240128831A (ko) | 2021-12-30 | 2024-08-27 | 베이진 스위찰랜드 게엠베하 | 브루톤 티로신 키나아제(btk) 억제제와 e3 리가아제 리간드의 접합에 의한 btk의 분해 및 사용 방법 |
| JP7825122B2 (ja) * | 2022-01-04 | 2026-03-06 | 上海科技大学 | Ｂｃｌ－２ファミリータンパク質リガンド化合物に基づいて開発したタンパク質分解剤及びそれらの応用 |
| EP4519259A1 (en) | 2022-05-06 | 2025-03-12 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
| WO2023215449A1 (en) | 2022-05-06 | 2023-11-09 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
| EP4519260A1 (en) | 2022-05-06 | 2025-03-12 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-xdegraders |
| CN115028679B (zh) * | 2022-08-11 | 2022-11-15 | 深圳湾实验室 | 一种具有Cyclophilin A降解活性的PROTAC化合物及其制备方法与应用 |
| CN120659777A (zh) * | 2022-10-03 | 2025-09-16 | 佛罗里达大学研究基金公司 | 募集Cereblon的Bcl-xL/Bcl-2双重降解剂 |
| WO2024078581A1 (en) * | 2022-10-12 | 2024-04-18 | Appicine Therapeutics (Hk) Limited | Selective bcl-xl protac compounds and uses thereof |
| WO2024153185A1 (zh) * | 2023-01-18 | 2024-07-25 | 苏州宜联生物医药有限公司 | 包含bcl-2家族蛋白降解剂的抗体药物偶联物及其制备方法和用途 |
| JP2026507476A (ja) * | 2023-02-17 | 2026-03-04 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | トリフルオロメタンスルホニル基を含む化合物 |
| WO2025101575A1 (en) | 2023-11-07 | 2025-05-15 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-x l degraders |
| TW202535872A (zh) | 2023-11-07 | 2025-09-16 | 美商樹線生物科學公司 | 四氫異喹啉異雙功能ｂｃｌ－ｘｌ降解劑 |
| TW202527930A (zh) | 2023-11-07 | 2025-07-16 | 美商樹線生物科學公司 | 四氫異喹啉異雙功能ｂｃｌ－ｘｌ降解劑 |
| WO2026015489A1 (en) * | 2024-07-08 | 2026-01-15 | University Of Florida Research Foundation, Incorporated | Bcl-xl/bcl-2 dual degraders and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7973161B2 (en) * | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| JP6817962B2 (ja) * | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| EP3270917A4 (en) * | 2015-03-18 | 2018-08-08 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| WO2017024317A2 (en) * | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| US10772962B2 (en) * | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| CN109152933B (zh) * | 2016-04-21 | 2022-12-02 | 生物风险投资有限责任公司 | 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途 |
| EP3454856B1 (en) * | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| WO2018106870A1 (en) * | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cdk4/6-mediated cancer |
| US20240398764A1 (en) * | 2021-10-12 | 2024-12-05 | University Of Florida Research Foundation, Incorporated | Methods of treating diseases associated with senescent cell accumulation |
| CA3241668A1 (en) * | 2021-12-09 | 2023-06-15 | University Of Florida Research Foundation, Incorporated | Bcl-xl/bcl-2 dual degraders for treatment of cancers |
-
2020
- 2020-02-07 CN CN202080027337.5A patent/CN113660937A/zh active Pending
- 2020-02-07 KR KR1020217028572A patent/KR20210137025A/ko not_active Ceased
- 2020-02-07 US US17/429,207 patent/US20220169628A1/en active Pending
- 2020-02-07 AU AU2020218367A patent/AU2020218367A1/en not_active Abandoned
- 2020-02-07 JP JP2021546264A patent/JP2022520061A/ja active Pending
- 2020-02-07 EP EP20753239.1A patent/EP3920923A4/en not_active Withdrawn
- 2020-02-07 WO PCT/US2020/017364 patent/WO2020163823A2/en not_active Ceased
- 2020-02-07 CA CA3127501A patent/CA3127501A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022520061A5 (https=) | ||
| JP2006523216A5 (https=) | ||
| JP2019517487A5 (https=) | ||
| JP2011057693A5 (https=) | ||
| JP2013545730A5 (https=) | ||
| JP2024054295A (ja) | ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法 | |
| JP2024546095A5 (https=) | ||
| JP2007520452A5 (https=) | ||
| CN110769837A (zh) | 与五氮杂大环状环配合物的联合癌症免疫疗法 | |
| JP2024147816A (ja) | がん治療における免疫モジュレーションのための組合せ | |
| JP2021534160A5 (https=) | ||
| CN101939001B (zh) | 用于治疗卵巢癌的含有紫杉醇的组合 | |
| JPWO2021187548A5 (https=) | ||
| JP6422936B2 (ja) | ５−ブロモ−インジルビン | |
| JP2009536956A (ja) | 抗癌治療法 | |
| US6355628B1 (en) | Combination therapy using pentafluorobenzenesulfonamides | |
| JP2022502378A5 (https=) | ||
| US6822001B2 (en) | Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents | |
| EP1757283B1 (en) | Antitumor effect fortifier, antitumor agent and method of therapy for cancer | |
| JP2023050198A (ja) | ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法 | |
| WO2013137433A1 (ja) | ３剤を組み合わせた新規な抗腫瘍剤 | |
| JP5409613B2 (ja) | 抗腫瘍剤、キット及び癌治療方法 | |
| JP2019525924A5 (https=) | ||
| RU2005131723A (ru) | Лечение пролиферативных заболеваний производными эпотилона и излучением | |
| JP2023514426A5 (https=) |